NutraStar Inc. announced Friday that its scientists have received a second diabetes patent (US Patent no. 6,350,473 B1), demonstrating that its stabilised rice bran derivatives reduce blood glucose levels, glycosylated hemoglobin levels and improve insulin synthesis in type 1 and type 2 diabetic subjects. This patent is owned by The RiceX Company, and is exclusively licensed to NutraStar Inc.